SBRT to Internal Mammary Lymph Nodes
Standard Indications for IMN Irradiation
- The decision to treat internal mammary nodes should be based on established risk factors, including axillary lymph node involvement with medial or central tumor location, according to the British Journal of Cancer and Annals of Oncology 1, 2, 4
- Medial or central tumor location is an indication for IMN treatment, regardless of nodal status, as recommended by the British Journal of Cancer 1
- Highest-risk patients after positive sentinel lymph node biopsy without axillary dissection should receive IMN treatment, including full level 1-4 treatment, as suggested by Annals of Oncology and other guidelines 2, 5
Technical Considerations for Conventional IMN Radiotherapy
- The standard dose for conventional IMN radiotherapy is 46-50 Gy in 23-25 fractions, as recommended by Annals of Oncology and other guidelines 2, 4, 3
- The target volume for IMN radiotherapy should include the most caudal lymph nodes in the first 3-5 intercostal spaces, as suggested by Praxis Medical Insights and other guidelines 5
- Critical constraint for IMN radiotherapy is to minimize heart and lung exposure using CT-based planning, as recommended by British Journal of Cancer and Journal of Clinical Oncology 1, 6, 7, 3
Clinical Algorithm for IMN Treatment Decision
- Step 1: Determine if IMN irradiation is indicated, based on factors such as positive axillary nodes and medial/central tumor location, as recommended by British Journal of Cancer and Annals of Oncology 1, 2
- Step 2: Select radiation technique, with conventional fractionation (46-50 Gy/23-25 fractions) recommended for primary adjuvant treatment, as suggested by Annals of Oncology and other guidelines 2, 4, 3
- Step 3: Technical planning should include CT-based planning to delineate IMN vessels with 7-mm expansion, and ensure adequate coverage and minimal cardiac toxicity, as recommended by Praxis Medical Insights and other guidelines 5, 3